Cellworks - About the company
Cellworks is a series B company based in San Jose (United States), founded in 2005 by Taher Abbasi and Shireen Vali. It operates as a Developer of a biosimulation platform. Cellworks has raised $16.5M in funding. The company has 114 active competitors, including 34 funded and 4 that have exited. Its top competitors include companies like Life Bit, IMU Biosciences and ICarbonX.
Company Details
Developer of a biosimulation platform. It has developed a biosimulation platform that uses computational modeling and offers the life science industry a framework for designing therapeutics to transform entirely empirical drug development. The platform is used for predicting responses to FDA-approved cancer therapies, & provides personalized cancer therapy recommendations.
- Website
- cellworks.life
- Social
- Registered Address
- South San Francisco, California
Key Metrics
Founded Year
2005
Location
San Jose, United States
Stage
Series B
Total Funding
$16.5M in 2 rounds
Latest Funding Round
Investors
Ranked
1st among 114 active competitors
Annual Revenue
₹10 - ₹50 Cr as on Mar 31, 2025
Employee Count
158 as on Sep 30, 2026
Legal entities associated with Cellworks
Cellworks is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
CELLWORKS RESEARCH INDIA PRIVATE LIMITED CIN: U72900KA2006PTC039107 , India, Active | Apr 25, 2006 | ₹10 - ₹50 Cr (As on Mar 31, 2025) | - | |
CELLWORKS GROUP, INC. CIN: 203556125 , United States, Active | Dec 31, 1999 | - | 7 (As on Dec 31, 2024) | - |
Sign up to download Cellworks' company profile
Cellworks's funding and investors
Cellworks has raised a total funding of $16.5M over 2 rounds. Its first funding round was on Apr 16, 2009. Cellworks has 5 institutional investors.
Here is the list of recent funding rounds of Cellworks:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 26, 2012 | 2328802 | Series B | 2230826 | 9549115 | 3050976 | 3119192 |
Apr 16, 2009 | 6250256 | Series A | 3343102 | 7228174 | 7748584 | 9885279 |
Access funding benchmarks and valuations. Sign up today!View details of Cellworks's funding rounds and investors
Cellworks' founders and board of directors
Founder? Claim ProfileThe founders of Cellworks are Taher Abbasi and Shireen Vali.
Here are the details of Cellworks' key team members:
- Taher Abbasi: Former Co-Founder & COO of Cellworks and founder of 1 other company. Contact Info: 1 email address and 1 phone number
- Shireen Vali: Former Co-Founder & CSO of Cellworks and founder of 1 other company. Contact Info: 1 email address and 1 phone number
View details of Cellworks's Founder profiles and Board Members
Cellworks' employee count trend
Cellworks has 158 employees as of Sep 26. Here is Cellworks's employee count trend over the years:
Uncover Cellworks' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Cellworks's Competitors and alternates
Top competitors of Cellworks include Life Bit, IMU Biosciences and ICarbonX. Here is the list of Top 10 competitors of Cellworks, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Cellworks 2005, San Jose (United States), Series B | Developer of a biosimulation platform | $16.5M | 66/100 | |
2nd | Life Bit 2017, London (United Kingdom), Series B | AI and SaaS-based genomics analysis software for drug development | $70.9M | 57/100 | |
3rd |  IMU Biosciences 2019, London (United Kingdom), Series A | Provider of immune discovery platform for precision medicines | $53M | 56/100 | |
4th | Provider of bioinformatic platforms for health management and drug development | $366M | 55/100 | ||
5th | Biostate 2023, Houston (United States), Series A | Developer of generative AI based RNAstate research platform to predict future omics states | $16M | 54/100 | |
6th | Provider of an AI-enabled immunotherapy based tumor diagnostic platform | $38.2M | 51/100 | ||
7th |  Liquid Biosciences 2017, Aliso Viejo (United States), Series C | Provider of bio-analytics platform to identify the biological and behavioral truth driving patient outcomes | $40.1M | - | 51/100 |
8th |  Watershed 2019, Sacramento (United States), Series A | Provider of software solution for biological data analysis, discovery, and collaboration | $19.7M | 48/100 | |
9th |  ROSALIND 2013, San Diego (United States), Seed | Cloud-based collaborative bioinformatics platform for researchers | $70K | 47/100 | |
10th | Provider of AI-driven solutions for drug discovery and clinical development | - | 44/100 |
_1568349958328.png?devicePixelRatio=2&height=30&width=30){kind=logo}
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Cellworks's competitors? Click here to see the top ones
Cellworks's Investments and acquisitions
Cellworks has made no investments or acquisitions yet.
Reports related to Cellworks
Here is the latest report on Cellworks's sector:
News related to Cellworks
Filter this listMedia has covered Cellworks for a total of 3 events in the last 1 year, 3 of them have been about company updates.
•
Cellworks Expands Evidence for Predicting Chemo-Immunotherapy Benefit in NSCLC with New Early-Stage Disease StudyCellworks•Apr 22, 2026•Cellworks
•
Cellworks Presents Novel Mechanistic Approach to Predicting Drug–Drug Interaction Risk in Oncology at AACR 2026Cellworks•Apr 22, 2026•Cellworks
•
Cellworks Study Supports Liquid Biopsy for Predicting Chemo-Immunotherapy Benefit in Advanced NSCLCCellworks•Apr 22, 2026•Cellworks
•
Cellworks Unveils a Breakthrough in Predicting Chemo-Immunotherapy Benefit for Patients with Metastatic NSCLCBusiness Wire•Sep 08, 2025•Cellworks
•
Cellworks’ Computational Biosimulation Lab Secures CLIA Certification to Advance Personalized Therapy Decision SupportBusiness Wire•Jan 13, 2025•Cellworks
•
Cellworks Enhances TRI with Personalized Tumor Microenvironment Modeling to Predict Overall Survival in NSCLC Patients Receiving ImmunotherapyBusiness Wire•Nov 12, 2024•Cellworks
•
Cellworks Biosimulation Combined with Tumor Microenvironment Modeling Enhances Predictions of IO Response in NSCLC PatientsBusiness Wire•Sep 16, 2024•Cellworks
•
Dr. Michael Donovan Joins Cellworks to Oversee Personalized Cancer Therapy Biosimulation in New CLIA-Certified LabBusiness Wire•May 28, 2024•Cellworks
•
Cellworks Expands Into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical AssetsBusiness Wire•Jan 09, 2023•Cellworks
•
Cellworks Wins Dell Technologies The Challengers 2022 Innovative Business of the Year AwardBusiness Wire•Sep 07, 2022•Cellworks
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Cellworks
Explore our recently published companies
- Clarinda Lauren - Saint Louis based, 2018 founded, Unfunded company
- AP LMEC Systems - Hyderabad based, 1996 founded, Unfunded company
- Facilitator On Fire - Galena based, 2015 founded, Unfunded company
- United Construction Est - Qatar based, 1975 founded, Unfunded company
- Char Man Brand - Unfunded company
- Americana Fence - Chicago based, Unfunded company
